Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/19/2024 | $72.00 | Buy | Guggenheim |
12/10/2024 | $66.00 | Neutral | UBS |
12/5/2024 | $60.00 | Sell → Neutral | Goldman |
10/15/2024 | $75.00 | Overweight | Barclays |
9/30/2024 | Outperform → Peer Perform | Wolfe Research | |
8/28/2024 | $78.00 | Overweight | Wells Fargo |
6/3/2024 | $85.00 | Buy | Jefferies |
2/14/2024 | $60.00 → $90.00 | Neutral → Overweight | JP Morgan |
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic
ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral disease ELITechGroup has its R&D, manufacturing and commercial focus on Europe and the Americas Bruker to acquire ELITechGroup revenues of ~Euro 150 million p.a. with >80% consumables revenue Bruker Corporation (NASDAQ:BRKR) announced today that
Chemspeed Accelerates Bruker's Laboratory Automation and Digitalization Drive Bruker Corporation (NASDAQ:BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125759758/en/Chemspeed's modular, compact FLEX automation workstations enhance chemical and materials science R&D and lab
Bruker Corporation (NASDAQ:BRKR) announced today that its senior leadership will present at the following conferences: Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York City Thursday, February 27, 2025, at 2:30 p.m. Eastern Time TD Cowen 45th Annual Health Care Conference in Boston, MA Wednesday, March 5, 2025, at 11:10 a.m. Eastern Time Barclays 27th Annual Global Healthcare Conference in Miami, FL Tuesday, March 11, 2025, at 2:30 p.m. Eastern Time Leerink 2025 Global Healthcare Conference in Miami, FL Wednesday, March 12, 2025, at 11:20 a.m. Eastern Time Live audio webcasts of the presentations will be available on the Investor Relations section of the Company's we
Q4 2024 revenues of $979.6 million, up 14.6% year-over-year (yoy); Bruker organic revenue up 3.9%, and constant-exchange rate (CER) revenue up 15.8%; Bruker Scientific Instrument (BSI) segment organic revenue up 4.5% Q4 2024 non-GAAP operating margin of 18.1%, as operational excellence and integration initiatives fully offset strategic M&A and FX operating margin headwinds Q4 2024 GAAP diluted EPS $0.09; non-GAAP diluted EPS $0.76, up 8.6% yoy FY 2024 revenues of $3.37 billion, up 13.6% yoy; Bruker organic revenue up 4.0%, and CER revenue up 14.0%; BSI segment organic revenue up 4.2% FY 2024 GAAP diluted EPS $0.76; non-GAAP diluted EPS $2.41, down 6.6% yoy, due to impact of str
Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00
UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00
Goldman upgraded Bruker from Sell to Neutral and set a new price target of $60.00
Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q3 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-
3 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)